| Developers: | Gilead Sciences |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2024: Recall of bladder cancer drug
In October 2024, Gilead Sciences announced a voluntary recall of its drug Trodelvy for the treatment of metastatic urothelial cancer in the United States. The decision came after consultation with the U.S. Food and Drug Administration (FDA).
The manufacturer admitted the drug showed no improvement in survival in patients with advanced bladder cancer, leading to the recall. Despite this, Gilead stressed that this decision will not affect the use of Trodelvy for other indications both in the United States and beyond.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |